Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 3100
- Registration Number
- NCT02416388
- Locations
- 🇫🇷
CH Amiens Hôpital Sud, Amiens, France
🇫🇷CHU Angers, Angers, France
🇫🇷CH Victor Dupouy, Argenteuil, France
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
- Conditions
- Acute Myeloid Leukemia (AML)Multiple MyelomaNon-Hodgkins LymphomaCancerNon-Small Cell Lung CancerProstate CancerSmall Cell Lung CancerBreast Cancer
- Interventions
- Drug: ABBV-075
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 128
- Registration Number
- NCT02391480
- Locations
- 🇺🇸
Scottsdale Healthcare /ID# 132963, Scottsdale, Arizona, United States
🇺🇸City of Hope /ID# 154053, Duarte, California, United States
🇺🇸UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 36
- Registration Number
- NCT02351037
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Drug: SGI-110 (guadecitabine)Drug: Treatment Choice
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 815
- Registration Number
- NCT02348489
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Scripps Cancer Center, La Jolla, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 148
- Registration Number
- NCT02343939
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: IA regimenDrug: IAC regimen
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 618
- Registration Number
- NCT02323022
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Registration Number
- NCT02303782
Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT02302846
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Ashkan Emadi
- Target Recruit Count
- 5
- Registration Number
- NCT02283190
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
- Conditions
- Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT02269579
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Shands Cancer Hospital @ University of Florida, Gainesville, Florida, United States
🇺🇸Franciscan St. Francis Health, Indianapolis, Indiana, United States